Provider Consolidation: Implications for Costs and Quality in Health Care Delivery: A Health Policy and Bioethics Consortium
In the last decade, the traditional conception of individual physicians or medical groups has been increasingly replaced by consolidation under academic medical centers and other national or regional administrative organizations. What are the implications of such organizational changes for patient care, and how has this trend contributed to overall rising health care costs? How well are antitrust laws designed to ensure proper government oversight of mergers and the entities that result?
This event is free and open to the public, but space is limited and registration is required. Please note that attendees will need to show ID in order to enter the venue. Register now!
Panelists
-
Leemore Dafny, PhD, Bruce V. Rauner Professor of Business Administration, Harvard Business School
-
Eric Gold, JD, Assistant Attorney General and Chief, Health Care Division, Massachusetts Attorney General's Office
-
Commentator: Jonathan J. Darrow, SJD, LLM, JD, MBA, Instructor in Medicine, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital
The Health Policy and Bioethics Consortia is a monthly series that convenes two international experts from different fields or vantage points to discuss how biomedical innovation and health care delivery are affected by various ethical norms, laws, and regulations.
They are organized by the Harvard Medical School Center for Bioethics and the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital, in collaboration with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Support provided by the Oswald DeN. Cammann Fund at Harvard University.
Tags
bioethics doctor patient relationship health care costs health law policy health policy and bioethics consortia market medical safety regulation